Leerink analyst Joseph Schwartz believes Intercept Pharmaceuticals is likely to receive a positive FDA panel vote on April 7 and win approval in primary biliary cirrhosis by the revised FDA action date of May 29. The analyst, however, expects the product launch to be slow and believes consensus expectations look "overly aggressive." While a potential takeout of Intercept remains a "wild card," suitors will be most interested in the company's Nonalcoholic Steatohepatitis, or NASH, opportunity, which has a "long runway for enrollment/treatment before data will mature," Schwartz tells investors in a research note. He reiterates a Market Perform rating on the shares with a $144 price target.